Inventor
MOHAMAD MORSEY
Inventor
US
Overview
Patents· 14 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes28%
C07KPeptides23%
C12NMicroorganisms or enzymes16%
PatentTitleYear
12,577,310Caninized antibodies to canine interleukin-31 receptor 202612,552,864Caninized antibodies to human CTLA-4202612,545,738Canine interleukin-4 receptor 202612,514,922Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens202612,435,143Caninized antibodies against canine CTLA-4202512,252,536Caninized antibodies202512,239,704Recombinant non-pathogenic Marek's disease virus constructs encoding multiple heterologous antigens202512,221,486Caninized human antibodies to human IL-4R alpha202512,180,288Antibodies to canine interleukin-4 receptor alpha202411,680,097Antibodies against canine PD-1202311,596,687Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens202311,447,561PD-L1 antibodies binding canine PD-L1202211,248,047Caninized antibodies202211,229,698Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to INTERVET INC (14)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| INTERVET INC | 14 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 14 | 2022–2026 |